Susan O’Brien SUSAN O’BRIEN, MD Anderson Cancer Center, Houston For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamid
Susan O’Brien
SUSAN O’BRIEN, MD Anderson Cancer Center, HoustonFor patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy.Susan O’Brienpresented data from this phase III trial to the American Society of Hematology meeting in Atlanta. Sarah Maxwell reports.
Tags
Related Episodes
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer
Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer
Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer An interview with: Jonathan Wesley Riess MD, Professor of Medic
Aditya Bardia MD MPH; 2025 San Antonio Breast Cancer Symposium: Selective Estrogen Degrader Giredestrant Improves on Standard Endocrine Therapy for Patients with ER-positive, HER2-negative Early Breast Cancer: Phase III lidERA Breast Cancer trial Findings
A seective estrogen degrader out-performed AI’s in ER+ HER- early breast cancer